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Abstract
Coconut, Cocos nucifera L., is a tree that is cultivated to provide a large number of products, although it is mainly grown for its nutritional
and medicinal values. Coconut oil, derived from the coconut fruit, has been recognised historically as containing high levels of saturated
fat; however, closer scrutiny suggests that coconut should be regarded more favourably. Unlike most other dietary fats that are high in
long-chain fatty acids, coconut oil comprises medium-chain fatty acids (MCFA). MCFA are unique in that they are easily absorbed and
metabolised by the liver, and can be converted to ketones. Ketone bodies are an important alternative energy source in the brain, and
may be beneficial to people developing or already with memory impairment, as in Alzheimer’s disease (AD). Coconut is classified as a
highly nutritious ‘functional food’. It is rich in dietary fibre, vitamins and minerals; however, notably, evidence is mounting to
support the concept that coconut may be beneficial in the treatment of obesity, dyslipidaemia, elevated LDL, insulin resistance and hyper-
tension – these are the risk factors for CVD and type 2 diabetes, and also for AD. In addition, phenolic compounds and hormones (cytokinins)
found in coconut may assist in preventing the aggregation of amyloid-b peptide, potentially inhibiting a key step in the pathogenesis of AD.
The purpose of the present review was to explore the literature related to coconut, outlining the known mechanistic physiology, and to discuss
the potential role of coconut supplementation as a therapeutic option in the prevention and management of AD.
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In line with the global predictions for the prevalence
of Alzheimer’s disease (AD), Australia declared AD as the
ninth National health priority in 2012. Alzheimer’s is a com-
plex disease that progresses over many years, such as
diabetes, heart disease and other chronic conditions. The
gradual accumulation of the pathology of cerebral extra-
cellular AD known as amyloid, which is mostly composed of
aggregated amyloid-b (Ab) peptides(1), as well as the
accumulation of intracellular neurofibrillary tangles, appears
to start up to 17–20 years before a clinically observable
disease(2). A number of factors may increase or decrease an
individual’s chances of developing the disease. These risk
factors include age, genetics, environment, lifestyle and meta-
bolic diseases.
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Diet may play an important role in preventing AD. As many
studies have linked AD risk to diet-modifiable conditions such
as type 2 diabetes, hypertension and CVD, dietary approaches
to AD prevention involving palatable, low risk, inexpensive
substances are attracting great attention, as a method to
ameliorating deficits concomitant with ageing and neurode-
generation. In particular, recent literature has suggested that
the use of coconut oil (extra virgin/virgin), coconut water
and coconut cream may have significant positive effects on
the lowering of plasma cholesterol, blood pressure (BP) con-
trol and blood glucose levels, all of which are risk factors
associated with AD. Coconut has also been identified as a
potential cognitive strengthener(3,4) associated with AD. The
present review reported the evidence for coconut oil con-
sumption, with a particular emphasis on virgin coconut oil
(VCO), outlining the potential risks and benefits in relation
to AD prevention and/or management.
The scientific name for coconut is Cocos nucifera, and the
plant is a member of the Arecaceae family(5–10). Among the
components of coconut, coconut oil is of the most interest
related to human health. Of note, coconut oil is principally
composed of SFA (about 92 %), with 62–70 % being
medium-chain TAG (MCT)(4,11,12), making coconut oil
unique among dietary fats. A few clinical trials and animal
studies using a formulation of MCT have reported significant
improvement of cognition in AD patients. While research on
Alzheimer’s and MCT is still in its infancy, the science
behind MCT is that MCT can be rapidly metabolised to
induce metabolic ketosis and ketogenic, which could be
employed as a therapy for a variety of brain disorders, includ-
ing epilepsy and neurodegeneration. Anecdotes via the media
and word-of-mouth have promoted great interest in the action
of ketones and, thus, coconut oil.
Recent studies have investigated the possibility of using
trans-zeatin and phyto-oestrogen and other sex hormone-
like substances present in coconut water and young coconut
juice in reducing the risk of AD(13,14). In contrast, experimental
studies have suggested that coconut/coconut cream consump-
tion can cause hyperlipidaemia and atherosclerosis, which are
risk factors for AD. In contrast, several studies have reported
that hyperlipidaemia and heart diseases are uncommon
among high coconut consuming populations(15,16).
In view of the interest in the potential of coconut oil, coco-
nut water and coconut cream as a dietary supplement that
could ameliorate the symptoms of neurodegeneration, we
analysed the literature to understand the influence of coconut
on the pathology of AD and risk factors for AD. Adding
complexity to this discussion is the various forms of coconut
available, and also the method of extraction used to produce
the end product.
Coconut oil
Coconut oil is extracted by either hot or cold pressed tech-
niques, and the method used is reported to influence the
quality and grade of the oil, although agreement on which
method is best has not been achieved. Both wet and dry
methods are used, and some approaches also involve solvents
for the final extraction, if using coconut expeller cake(4). VCO,
manufactured using controlled temperature (hot or cold)
methods are thought to be the most effective methods if
aiming to retain the highest levels of biologically active com-
ponents such as tocotrienols, squalene (hydrocarbon, import-
ant for animal steroid formation), tocopherols and sterols
(phytosterols)(3). This is in contrast to copra oil (derived
from the dried coconut meat or kernel) that is processed
with no temperature control(3,17). VCO is natural, chemically
unrefined and considered safe for human consumption(4).
Thus, in addition to being used as a cooking oil, VCO can
also be considered as a functional food supplement. The
total phenolic content of VCO (7·78–29·18 mg gallic acid
equivalents/100 g oil) is significantly higher than that of
refined coconut oil (6·14 mg gallic acid equivalents/100 g
oil)(4,18). However, there is no significant difference in fatty
acid content among VCO, Copra and refined coconut oil, all
containing 92 % SFA, 6 % MUFA and 2 % PUFA. However,
VCO has shown greater beneficial effects than copra oil in
lowering lipid levels in serum and tissues and in reducing
LDL oxidation by physiological oxidants. This property of
VCO may be attributed to the biologically active polyphenol
components present in the oil(19).
Not surprisingly, the high levels of saturated fat have gener-
ally deterred those who are more health conscious from using
coconut oils, cream or milk. Furthermore, low-fat diets have
been considered to be the best approach to reduce the risk
of AD, in particular the Mediterranean diet(20,21). Therefore,
promoting coconut oil as a food would appear counter-
intuitive. However, closer scrutiny of the chemical properties,
digestion and uptake may suggest that this concern may not
be well founded. Coconut oil is rich in medium-chain
fatty acids (MCFA), which are metabolised differently to the
long-chain fatty acids (LCFA) commonly found in human
diets. In addition, coconut oil offers anti-ageing and anti-
oxidant properties(22,23). Coconut oil in food has a long
history, and is very popular in South Asia and has a prominent
place in Ayurvedic medicine.
Coconut oil consists mostly of medium-chain fatty acids
Coconut oil is principally composed of SFA (about 92 %), with
62–70 % being MCFA(4,11,12) (Table 1), making coconut oil
Table 1. Fatty acid composition of coconut oil, showing percentage of
total fat





Caproic acid (6 : 0) 0·6 Saturated MCFA
Caprylic (8 : 0) 0·8 Saturated MCFA
Capric (10 : 0) 6·4 Saturated MCFA
Lauric (12 : 0) 48·5 Saturated MCFA
Myristic (14 : 0) 17·6 Saturated MCFA
Palmitic acid (16 : 0) 8·4 Saturated MCFA
Stearic acid (18 : 0) 2·5 Saturated LCFA
Linoleic acid (18 : 1) 6·5 Unsaturated LCFA
Linolenic (18 : 2) 1·5 Unsaturated LCFA
MCFA, medium-chain fatty acids; LCFA, long-chain fatty acids.

















unique among dietary fats(3,11). The difference between MCFA
and LCFA is the length of the fatty acid carbon chain. MCFA
have a chain length of six to twelve carbons(3,24) (Table 1),
whereas LCFA contain fourteen or more carbons(11,24). The
length of the carbon chain determines the physical and chemi-
cal properties of the fats as well as their metabolism in the
human body(24). Soya oil contains 60 % PUFA, 24 % MUFA
and 16 % SFA(25). In contrast, palm oil contains 50 % MUFA
and 50 % SFA. This high level of PUFA of soya oil can improve
the blood lipid profile status(26). In addition, with its high
content of tocopherols, soya oil is known to exhibit various
antioxidant actions against lipid peroxidation.
Metabolism of medium-chain fatty acids
MCFA are broken down almost immediately by enzymes in
the saliva and gastric juices, without the need for pancreatic
fat-digesting enzymes(27); furthermore, this process involves
relatively moderate energy consumption. Therefore, the
metabolism of coconut oil is significantly different from that
of other fatty acids commonly found in the diet(18).
Medium-chain fatty acid absorption
In the case of most other fatty acids and cholesterol, the
intestines play a major role in absorption(28); yet unfortunately,
pancreatic function declines with age, and therefore malabsorp-
tion problems can occur in patients who suffer from digestive
and metabolic conditions. In other words, as the pancreatic
output of digestive enzymes reduces, the efficiency of the
small intestine in the absorption of nutrients diminishes(27–30).
This is important, as vitamin and mineral deficiencies are recog-
nised as a global health issue(31), and age-related changes
and select disease processes exacerbate this problem(29,32,33).
As weight loss and malnutrition are recognised as frequent
companions and contributors to AD, dietary supplementation
with coconut oil may help prevent weight loss and increase
the intake of certain vitamins and minerals.
The concern that coconut oil may increase plasma lipid
levels and adversely affect health is a point of contention.
MCFA are partially hydrolysed from dietary TAG by lingual
lipase in the stomach and completely digested by pancreatic
lipase within the intestinal lumen(27). Therefore, MCFA are
absorbed directly from the intestines into the portal vein and
sent straight to the liver(27,33). Unlike MCFA, other fats such
as cholesterol, as well as saturated fat, monounsaturated fat
and polyunsaturated fat containing LCFA, combine with pro-
teins and form lipoproteins(24,27,33,34). These lipoproteins
enter the bloodstream via the lymphatic system, thus mostly
bypassing the liver(27,33). As lipoproteins circulate in the
blood, their fatty components are dispersed to tissues(35),
therefore contributing to the accumulation of fat in such
body tissues, as part of normal fat storage. However, in the
process, some of these fats congeal within the artery walls,
increasing the risk of hypertension and adding to the cardio-
vascular risk factors, and both known to increase AD risk(21).
In contrast to LCFA that are easily esterified and bind strongly
to fatty acid binding proteins(36,37), MCFA are not easily
esterified and resist binding. Thus, MCFA are less likely to
contribute to such fat deposits, and thus have reduced
impact on the cardiovascular system, including BP(34,35,38,39).
However, recent research with VCO has demonstrated that
repeatedly heated VCO causes an elevation in BP. BP
elevation has been associated with a significant increase
in the inflammatory biomarkers (vascular cell adhesion
molecule-1, intercellular adhesion molecule-1 and C-reactive
protein), thromboxane A2 and a significant reduction in the
plasma PGI2 level
(40). Repeatedly heated soya oil and palm
oil also elevated BP(41,42).
Medium-chain fatty acid breakdown
Similar to the absorption differences mentioned above, the
human body metabolises MCFA and LCFA via different path-
ways(33,43). SCFA are transported in the blood as NEFA,
while longer-chain NEFA are combined with albumin(11).
The metabolism of fatty acids is initiated on the outer
mitochondrial membrane and is catalysed by acyl-CoA synthe-
tase(43) as shown in Fig. 1. This step is required partly to
enable the transport of the fatty acids into the mitochondrial
matrix. First, the fatty acid forms an acyl-adenylate; then
while still tightly bound to the enzyme, acyl-adenylate is con-
verted to acyl-CoA (medium-chain acyl-CoA or long-chain
acyl-CoA) and AMP(43). Acyl-CoA can then be transported
into the mitochondria using different pathways depending
on the fatty acid chain length(43). Long-chain acyl-CoA
molecules conjugate with carnitine (L-3-hydroxy-4-aminobu-
tyrobetaine or L-3-hydroxy-4-N-trimethylaminobutanoic acid,
and its acyl-esters (acylcarnitines)(43,44) to form acylcarnitine,
and this reaction is catalysed by carnitine acyltransferase
I(43). In contrast, MCFA enter the mitochondria independently
of the carnitine transport system(45), and therefore do not
depend on the activity of the carnitine acyltransferase-1
enzyme, as with LCFA(43). Medium-chain fatty acyl-CoA
molecules easily transfer into the mitochondria and can then
be converted into acetoacetate (AcAc) and b-hydroxybutyrate,
mainly by medium-chain fatty acyl-CoA-dehydrogenase(45).
These two products can be metabolised further in the liver
to produce CO2, H2O and energy
(29,33,45).
Benefits of medium-chain fatty acids compared with
long-chain fatty acids
The result of the quicker metabolic conversion of MCFA is that
instead of being deposited as fat, the energy generated from
MCFA is very competently converted into fuel for immediate
use by organs and muscles. Furthermore, MCFA produce
34·7 kJ/g (8·3 kcal/g) ingested, whereas LCFA will produce
38·5 kJ/g (9·2 kcal/g) ingested(4). Thus, MCFA provide about
10 % less energy than LCFA. Although the difference sounds
insignificant, this is just one of the many advantages of
Fatty acids + ATP Acyl adenylate+PPi
Acyl adenylate +HS-CoA Acyl CoA +AMP  
Fig. 1. Formation of acyl-CoA.

















MCFA, as it will reduce obesity to some degree, and obesity is
an independent risk factor for hypertension, hyperlipidaemia
and diabetes, which are, in turn, the risk factors associated
with AD(46).
Differences between LCFA and MCFA metabolism may also
help in other more indirect ways in controlling obesity, and
differences in the metabolism as well as the metabolic
effects of LCFA and MCFA have been demonstrated in both
animal and human studies(47–49): for example, increases in post-
prandial energy expenditure (EE) as well as the attenuation of
weight accretion have been demonstrated, after short- or
longer-termMCFAconsumption, and these arediscussedbelow.
In early clinical studies, Flatt et al.(50) compared diets rich in
either MCFA, LCFA or low in fats, and found that low-fat diets
were most efficient for weight loss; however, they also found
that MCFA-rich diets may be better than LCFA-rich diets; this
was supported by Hill et al.(51) who reported that higher EE
was achieved through MCFA intake over 7 d when consumed
in liquid formulation. This study demonstrated that excess
dietary energy as MCFA motivated thermogenesis to a higher
degree than did excess energy as LCFA. This higher EE
induced by MCFA is most likely due to increased metabolic
rates and thermogenesis. In a trial involving six participants,
Scalfi et al.(52) introduced meals containing 30 % fat, in the
form of maize oil and animal fat, or MCFA oil (56 % octanoate
and 40 % decanoate), to evaluate EE. They found that EE after
consumption of MCFA (compared with LCFA) was 48 %
greater in lean individuals, and 65 % greater in obese individ-
uals. Dulloo et al.(53) compared the effects of low-to-moderate
amounts of MCFA and LCFA consumption in eight healthy
adult men. Subjects were given MCFA and LCFA (30 g total)
at (g:g) ratios of 0:30, 5:25, 15:15 and 30:0, and their EE
were measured. Increases in EE of 45, 135 and 265 kJ were
reported following 5, 15 and 30 g of MCFA in the diet, respect-
ively, suggesting an approach to altering body fat composition
and metabolism. White et al.(54), however, cautioned that the
anti-obesity effect of MCFA results could be transient, as
they found that short-term feeding of MCFA-enriched diets
increased temporary EE, yet with longer intake, this benefit
was reduced. Encouragingly, however, a double-blind con-
trolled trial in men and women (n 78) over a 12-week
period demonstrated a greater reduction in body weight and
fat following the daily ingestion of 60 g/d of MCFA compared
with 60 g/d LCFA(35), with other major dietary parameters not
being significantly different. Furthermore, several studies have
now shown that EE is higher when diets contain MCFA rather
than LCFA; thus, MCFA are more conducive to weight
loss(47,55–58). The above studies are encouraging, yet may
need to be repeated in larger cohorts to give the results further
validation. However, a recent study in 2010 has concluded that
there is no evidence that fatty acid chain length has an effect
on the measures of appetite and food intake when assessed
following a single high-fat test meal in lean participants. This
study failed to observe any differences between SCFA (dairy
fat), MCFA (coconut oil) and LCFA (beef tallow) when
energy is held constant at a test meal(59). Hamsi et al.(40)
showed that heating of VCO repeatedly, which is a common
practise in order to save the cost, could have detrimental
effects on the body weight. This study demonstrated that
rats fed with VCO, repeatedly heated one, five and ten
times, resulted in higher weight gain than the non-heated
oil-fed group. This finding is not unique to coconut oil, but
is in line with earlier animal studies, which showed that
heated palm oil and soya oil resulted in greater body weight
gain compared with the control group(41,42).
PUFA play wide range of roles in cell metabolism, signalling
and inflammation. Of the PUFA, very-long-chain EPA and
DHA found principally in fish play key roles in metabolism
and inflammation. Some studies have suggested that
MCFA can enhance the positive effects of other dietary lipids
such as PUFA. Conjugated linoleic acid, such as fish oil, is
a popular dietary supplement marketed for its role in
enhancing fat metabolism(60). Conjugated linoleic acid is
purported to have several physiological functions, including
appetite suppression, increased fat mobilisation and
increased fatty acid oxidation(61), and in one study(37) of
mice fed conjugated linoleic acid, it has been found that the
addition of MCFA (through dietary coconut oil)is associated
with improved lipolysis (breakdown of TAG into glycerol
and NEFA) compared with diets containing conjugated linoleic
acid supplemented with soya oil. However, discrepancies exist
across publications; for example, a number of studies have
linked coconut oil to higher levels of LDL(13,18,19), higher
risks for CVD(18,19) and impairments in memory(15,16,18,19)
as well as in hippocampus morphology(16,18).
Medium-chain fatty acids can be converted to
ketone bodies
MCT or MCFA can act as a non-carbohydrate fuel source by
enhancing the formation of ketones or ketone bodies in the
body which are AcAc, 3-b-hydroxybutyrate (3HB) and
acetone(24) (see Fig. 2). The first two molecules are used for
energy production, whereas acetone is a breakdown product
of AcAc. Fatty acids cannot pass the blood–brain barrier
(BBB); thus, the human brain primarily depends on glucose.
However, it can utilise alternative fuels such as mono-
carboxylic acids, lactate and ketones to maintain energy
homeostasis(62,63), and ketone bodies are used extensively as
an energy source during glucose deficiency (ketosis)(64,65).
AcAc and 3HB are short-chain (four-carbon) organic acids
(ketone bodies) that can cross cell membranes freely(64), and
cross the BBB through proton-linked, monocarboxylic acid
transporters(64).
Ketone bodies are absorbed by cells and converted back to
acetyl-CoA, which enters the citric acid cycle (Krebs cycle) and









Fig. 2. Ketone bodies.

















precursors of acetylcholine(62) in neurons. Alternatively,
ketone bodies can be converted to acetyl-CoA in the brain
for the purpose of synthesising LCFA(62,64,67).
Ketogenic diets
Diets that comprise very low carbohydrate levels, substantial
amounts of protein and high fat levels have a capacity to
result in the production of high levels of ketone bodies
(3HB, AcAc and acetone) and are often known as ketogenic
diets (KD)(68). A KD has been found to be one of the most
effective therapies for drug-resistant epilepsy; it has also pro-
vided specific benefits in conditions such as GLUT protein I
(GLUT-I) deficiency, pyruvate dehydrogenase deficiency,
myoclonic astatic epilepsy (Doose syndrome), tuberous scler-
osis complex, Rett syndrome and severe myoclonic epilepsy
in infancy (Dravet syndrome)(69–74). Despite being used for
many decades, the mechanism whereby a KD can reduce epi-
lepsy is not understood. Recent research has suggested keto-
sis, reduced glucose, elevated fatty acid levels and enhanced
bioenergetics reserves, as well as neuron-specific effects
such as modulation of ATP-sensitive potassium channels,
enhanced neurotransmission, increased brain-derived neuro-
trophic factor expression due to glycolytic restriction and
reduced neuroinflammation may be involved.
Rats maintained on a KD display an altered influx of nutri-
ents to the brain, due to the up-regulation of both ketone
transporters and GLUT type 1(75–77). However, in early
studies, it has also been found that the classic KD leads to
a higher risk of atherosclerosis(78), a condition known to
increase the risk of AD. More recent studies have indicated
that the fatty acid content of the KD influences this risk of
atherosclerosis: the classic KD contains a 4:1 or 3:1 ratio (by
weight) of fat to combined protein and carbohydrate(79),
with most of this fat being LCFA. Later studies have found
that altered KD that are rich in MCFA, sometimes known as
the MCT-KD, are more nutritionally adequate than classic
KD, and are still effective in treating epilepsy disorders yet
reduce cardiac risk(80,81). The MCT-KD countenances more
fruits and vegetables, more food choices and causes lesser
incidence of kidney stones, hypoglycaemia, constipation,
low bone density and growth retardation(81).
The MCT-KD contains less fat overall, as it includes
MCFA (from coconut oil) that can provide a greater amount
of ketone bodies per gram of fat and thus allows more
carbohydrate and protein in the diet, making the diet more
palatable than the classic KD. KD rich in MCFA have signifi-
cant effects on lowering the cholesterol:HDL ratio compared
with the classic KD(80).
The use of glucose for energy is vital in the brain; yet, this
system is impaired in AD, partly due to disruption of the insu-
lin signalling mechanism(82). Low glucose utilisation has been
demonstrated in many studies by fluoro-2-deoxy-D-glucose
positron emission tomography imaging in AD subjects. Impor-
tantly, this has also been detected in elderly people who later
develop AD(83). In fact, the strikingly reduced expression in
the central nervous system of genes encoding insulin, insulin
like growth factor I (IGF-I ) and insulin like growth factor II
(IGF-II ), as well as the insulin and IGF-I receptors, suggests
that AD may represent a neuroendocrine disorder, which
has been termed ‘Type 3 diabetes’. Since energy provision
via glucose appears to be inadequate in emergent (pre-clini-
cal) AD as well as established AD, it has been suggested
that an enhanced supply of ketone bodies may be beneficial
due to the resultant enhanced ATP output of mitochon-
dria(69,76,84). In type 1 diabetic patients, who would also
benefit considerably from sources of energy other than glu-
cose to maintain brain energy homeostasis, an elevation in
3HB levels in plasma(63) has been observed when coconut
oil has been consumed.
The effectiveness of KD diets in raising ketone body levels
is measurable in plasma, as has been shown, for example, by
measuring increased 3HB levels in rat plasma(75). Significantly,
some clinical studies of AD or mild cognitive impairment
patients(63,75,85,86) have reported positive effects on cognitive
performance after consuming MCFA-rich foods, while also
observing significant increases in blood 3HB levels after treat-
ment (P ¼ 0·007)(85). However, in this last study, the cognitive
improvement has not been seen in ApoE-14 allele carriers
(carriage of ApoE-14 alleles increases AD risk). Later studies
investigating KD diets in AD patients have shown that KD
diets raised mean serum 3HB levels from about 0·1 mmol/l
to about 0·4 mmol/l in these patients(87). In this trial, AD
patients have demonstrated improvement in cognition when
measured at 45 and 90 d post ketone supplementation. How-
ever, the benefits were seen only in ApoE4-14 allele-negative
patients and resulted in adverse events including diarrhoea,
flatulence and dyspepsia. Additional research is important to
determine the therapeutic benefits of MCT for patients with
AD and how ApoE-14 status may mediate b-OHB efficacy.
Baran˜ano & Hartman(84) supported the concept that KD can
enhance the mitochondrial production of ATP, and prevent the
development of AD via numerous other pathways. Together
with ATP production, mechanisms proposed include altered
brain pH affecting neuronal excitability, direct inhibitory
effects on ion channels, increasing levels of both ketone trans-
porters and GLUT-1, increasing capillary density or improving
the regulation of sirtuins, a family of proteins that play a major
role in mediating anti-ageing effects of energy restriction.
In AD, the deposition of aggregated Ab peptides in the
brain is recognised as a hallmark feature of AD, and while
it is known that Ab is formed by proteolytic cleavage of the
amyloid precursor protein (APP) by various proteases,
the mechanisms that cause the peptide to accumulate in the
brain, aggregate and cause neuronal toxicity are not fully
understood(88). By providing an alternative energy source to
glucose, ketones may be able to sustain neuronal viability.
In support of this, a dual-tracer positron emission tomography
imaging study of rats on a KD showed that the diet caused
increases in brain uptake of the two tracers 11C-AcAc and
18F-fluorodeoxyglucose S(89). Later studies by the same
group have shown that a 14-d KD could increase the
cerebral metabolic rate of AcAc and glucose by 28 and 44 %,
respectively, in aged (24-month) rats(90). Another recent pilot
study(91), which investigated the effects of coconut oil
supplementation directly on cortical neurons treated with

















amyloid-(A) peptide in vitro, has indicated that neuron
survival in cultures co-treated with coconut oil and Ab is
rescued compared with cultures exposed only to Ab. Coconut
oil co-treatment also attenuated Ab-induced mitochondrial
alterations. The results of this pilot study have provided a
basis for further investigation of the effects of coconut oil, or
its constituents, on neuronal survival, focusing on the mechan-
isms that may be involved(91). There are some contrasting
results among the Animal studies. Van der Auwera et al.(92)
reported a decrease of Ab in the brain of young transgenic
AD mice over expressing the London APP mutation fed with
KD for 1·5 months, while study with aged dogs that has
reported the effect of KD on Ab is restricted to the parietal
lobe of the brain(93). Kashiwaya et al.(94) observed that long-
term (8 months) feeding of a ketone ester in middle-aged
mice (8·5 months old) improved cognition and reduced Ab
and t pathology. Another study(95) has demonstrated that
AD mice model fed with a high-fat, low-carbohydrate KD
shows improved motor function but without changes in Ab.
Providing further support for the benefits of high dietary
MCFA levels against AD, an in vitro study demonstrated that
the addition of ketone bodies (b-hydroxybutyrate) protects
the hippocampal neurons from Ab toxicity, thus suggesting
possible therapeutic roles for KD on mitochondrial defects
related to AD(69). Few studies have demonstrated that KD
could significantly improve glucose homeostasis, reducing
metabolic dysregulation and insulin resistance (IR), which is
important to reduce the pathology of AD(96–98).
Morris et al.(99) suggested that a high intake of unsaturated,
unhydrogenated fats may be protective against AD, proposing
that coconut oil may also be protective against AD. Despite
the positive effect of KD, how the KD affects b-amyloid
levels and whether this effect could be disease modifying in
AD requires further study.
Adverse effects of ketones
There is a paucity of data on the adverse effects of ketone
administration in the literature. A study has reported signifi-
cant rise in the mean blood cholesterol level to over
2500 mg/l following a prolonged intake of a KD(100). This
effect, in turn, may be atherogenic, leading to lipid deposition
in blood vessels. Some researchers have observed dilated car-
diomyopathy in patients on the KD, due to the toxic effects of
elevated plasma NEFA. Further, an increased incidence in
nephrolithiasis as well as increases in serum uric acid
levels has been reported(101,102). Some side effects are
common following administration of ketone bodies, such as
dehydration and hypoglycaemia. However, growth retar-
dation, obesity, nutrient deficiency, decreased bone density,
hepatic failure and immune dysfunction are also observed,
but not frequently(81,87).
Hiraide et al.(103) reported a significant increase in pH
and Na concentrations following the administration of a 20 %
solution of Na b-hydroxyl butyrate (BHB) to severe trauma
patients. Also, reduction in glucose cerebral metabolism and
the increase in cerebral blood flow were observed by Hassel-
balch et al.(104) during the administration of intravenous BHB.
The long-term consequences of these deviations are not yet
known.
KD with high-protein diets may cause possible kidney
damage due to high levels of N excretion during protein
metabolism(105). However, several researches have reported
that even high levels of protein in the diet do not damage
renal function(106). KD with very low carbohydrate can
cause a regression of diabetic nephropathy due to acido-
sis(107). As the concentration of ketone bodies never rises
above 8 mmol/l, this risk is minimum with normal insulin
function subjects(108).
Coconut oil as a source of antioxidants
Antioxidants are substances of natural and synthetic origin that
have a high potential to scavenge free radicals(109–111). The
development of AD has been linked to oxidative stress, and
studies have suggested that antioxidant-rich natural diets
may protect against AD. Although studies on the benefits for
AD have not been conclusive(109,110,112), many suggest that
combinations of (rather than individual) antioxidants are ben-
eficial(113). Coconut oil has a high percentage of phenolic
acids, and these are phytochemicals, sometimes also referred
to as a polyphenols. Phenolic acids are recognised for their
antioxidant properties. p-Coumaric acid, ferulic acid, caffeic
acid and catechin acid are the major phenolic acids found in
coconut oil(22). The hydroxyl group of phenolic compounds
may be able to reduce the toxicity of the Alzheimer’s Ab pep-
tide(114–118). In vitro studies that have investigated flavonoids
indicate that the hydroxyl groups could trap hydrogen bonds
of Ab, which is important as this may reduce Ab aggrega-
tion(114). It has also been shown that phenolic compounds
can bind Ab fibrils with their long axis parallel to the long
axis of Ab fibrils(119). Several other phenolic compounds
have been shown to prevent Ab aggregation and/or toxicity
such as resveratrol, catechin and curcumin(120,121). However,
despite the encouraging studies mentioned above, the exact
mechanisms by which the phenolic group affects Ab toxicity
is not currently clear. While data from AD studies(80–83) have
suggested the beneficial effects of phenolic compounds on
Ab-related pathology, some discrepancies still exist. For
example, recent work has demonstrated a significant inhi-
bition of Ab oligomers as well as higher growth of Ab
fibrils(122) by phenolic compounds. These controversial results
should be investigated further(123).
Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a
phenolic compound that has potent antioxidant and anti-
inflammatory activities(124,125). Ferulic acid, in particular, is
one of the phenolic compounds demonstrated to have
strong anti-Ab aggregation properties(126). Researchers have
found that the chronic administration of ferulic acid can
reduce cortical levels of Ab1-40 and Ab1-42 as well as IL-1b
levels in APP/PSI AD-model transgenic mice(127). Ferulic acid
has also been shown to inhibit Ab deposition in the
brain(127). However, another study has found that ferulic
acid could not prevent the formation of Ab fibrils, but
could reduce the length of the fibrils(128). It appears that
ferulic acid may be able to interrupt the elongation process

















by binding to the Ab fibrils(129). In other mouse studies, the
long-term administration of ferulic acids could suppress the
increase in glial fibrillary acidic protein and IL-1b immuno-
reactivity in the hippocampus that is induced by Ab 1–42
treatment(130).
p-Coumaric acid is another compound found in coconut oil
that has high antioxidant capacity(131). Maltolyl p-coumarate
had been found to attenuate cognitive deficits in rat models
and to cause a reduction in apoptotic cell death in the hippo-
campus of Ab1–42-infused rats. All these studies have
suggested that coconut oil contains many antioxidants with
the potential to reduce the development of AD pathology.
Coconut oil in insulin resistance and control of
plasma lipids
There are currently no effective AD treatments, and there is
currently no cure on the immediate horizon. As mentioned
earlier in this review, health issues, such as IR and obesity,
similar to CVD, disrupted cholesterol metabolism, type 2 dia-
betes and hypertension, are all risk factors for AD(132,133).
Recent studies, many of which have already been mentioned,
have shown that including coconut oil in the diet can reduce
the risk of these factors, and due to the major disruption in
insulin function that appears to happen early in the patho-
genesis of AD, this aspect has gained particular attention.
IR is a condition where cells fail to respond to the normal
actions of the hormone insulin(134). This results in hyperinsuli-
naemia that can eventually be diagnosed as type 2 diabetes.
Insulin and insulin receptors have been reported to be enriched
in brain areas where memory functions take place(134). There-
fore, impaired insulin regulation results in cognitive and
memory shortfalls, such as those observed in AD patients as
well as people with mild cognitive impairment(135). Insulin is
also an important regulator of proteins involved in the pathol-
ogy of AD, namely the APP, and t(136). Poor insulin action
leads to poor regulation of brain glucose levels, which, in
turn, can lead to an acceleration of neurodegeneration, due to
oxidative stress and increased Ab production from APP, both
of which are key steps in the pathogenesis of AD(88).
A higher rate of diabetes has developed in India and South
Pacific Islands following dietary changes from traditional fats
such as ghee and coconut oil to polyunsaturated fats such as
sunflower or safflower oils(137). Conversely, researchers have
observed that a diet rich in coconut oil shields against IR
in diabetic rats(138). Furthermore, a more recent study has
found that rats fed with LCFA and n-6 PUFA for 8 weeks
induce IR, and increased the expression of liver X-receptors
(LXRa), carbohydrate response element binding protein and
LCFA elongase-6 in the liver and white adipose tissue(139). In
contrast, the rats fed MCFA (from coconut oil) had reduced
LXRa, carbohydrate response element binding protein and
LCFA elongase-6 expression as well as improved insulin
signalling and less IR. In an in vitro study that compared
LCFA and MCFA effects in myotubes, it has been found
that MCFA-treated cells displayed less lipid accumulation, and
MCFA increased the intrinsic respiratory capacity of mitochondria
without increasing oxidative stress (less reactive oxygen species
generation)(140). Furthermore, in studies of thiazolidinediones,
ligands that increase insulin sensitivity in type 2 diabetes via
the PPARg, it has been found that certain MCFA such as those
in coconut oil (C8–C10) are low-potency agonists, yet without
the deleterious side effects(141). Such studies are beginning
to characterise the mechanisms involved in the insulin
signalling-protective effects of MCFA-containing diets. How-
ever, not all studies agree; for example, one study of male rats
on a MCFA-rich diet has found that the diet causes increases
in body adiposity and hyperinsulinaemia and reduces insulin-
mediated glucose uptake in the skeletal muscle(142), indicating
that further research is required to understand the metabolism
and effects of different MCFA.
The major components in coconut oil that are believed to
be involved in reducing IR are fatty acids (such as lauric
acid (45–50 %) and capric acid) and phenolic compounds
(such as ferulic acid and p-coumaric acid)(143,144). Levels of
the beneficial components are believed to be higher in
VCO, which, as mentioned earlier, is prepared via a cold or
low-heat-based extraction method. This oil contains higher
levels of phenolic acids than copra or refined coconut oil(4).
Coconut oil and lipid metabolism
The addition of VCO to the diet has also been associated with
a decrease in plasma LDL-cholesterol (LDL-C) and TAG levels
and an increase in HDL-cholesterol levels(19). In this rat study,
Nevin & Rajamohan(19) demonstrated that VCO has a higher
capacity to reduce serum LDL levels than copra oil, and to
reduce LDL oxidation by physiological oxidants. Another
study has concluded that coconut oil can lower cholesterol
synthesis in human subjects, possibly due to lower production
rates of apoB-containing lipoproteins(145).
Abnormal metabolism of lipoproteins such as lipoprotein
(a)/Lp(a) and their variants has been associated with periph-
eral artery disease, stroke, atherosclerosis, cerebrovascular
disease as well as AD(146,147). Coconut oil has been shown
to help reduce Lp (a) levels, and the addition of coconut oil
to the diet may improve cholesterol metabolism. In a study
of twenty-five women, it has been observed that lipopro-
tein(a) levels are 13 % lower after the women had consumed
a high-fat diet containing coconut oil (38·4 % of energy from
fat)(23). The same study has found that the postprandial
plasma concentration of tissue plasminogen activator antigen
(tPA antigen, often abnormally high in diabetes/IR)(148), has
dwindled when the women consumed the high-fat coconut
diet, when compared with women who had consumed a
diet high in unsaturated fat. Another study of women has
noted that dietary coconut oil intake has been positively
associated with HDL-cholesterol levels, especially among
pre-menopausal women; the study has also found that coco-
nut oil consumption did not cause a significant increase in
LDL-C or TAG levels(149). A meta-analysis(150) of prospective
epidemiological studies has demonstrated that dietary satu-
rated fat is not associated with an increased risk of CHD or
CVD. In contrast to these positive studies, Tsai et al.(151)
reported that both MCT and lauric acid raised serum LDL-C
concentrations compared with the more polyunsaturated

















baseline diet. Cater et al.(152) also showed that MCT have
one-half the potency that palmitic acid has at raising total
and LDL-C concentrations. Interestingly, in 2004, Tholstrup
et al.(34) observed that MCFA had a hypercholesterolaemic
effect. One study has noted that soya oil reduces cholesterol
to a greater degree than coconut oil with no influence
on HDL-cholesterol(153), and addition of Psyllium fibre
supplementation lowers serum cholesterol regardless of satur-
ation level of dietary fat(153). As cholesterol metabolism and
AD pathology have been shown to be linked(147), further clini-
cal research is required to understand the contribution of
coconut oil to cholesterol metabolism and AD. Nevertheless,
due to the many likely benefits of VCO, most researchers
would recommend the inclusion of coconut oil in the diet;
however, researchers are yet to decide how much coconut
oil is required for optimal health. Two studies have rec-
ommended a daily intake of 3·5 tablespoons of VCO for a
72 kg man(154,155). This was based on the quantity of MCFA
present in human breast milk. Interestingly, VCO and
human breast milk have more saturated fats than mono- or
poly-unsaturated fats, and in both cases, the main fat is
lauric acid, with VCO containing the most, at about
50 %(155). However, coconut dosage to enhance the memory
of impaired people has not been concluded.
Apart from the benefits already mentioned above, both
lauric acid, the main fatty acid in coconut, and phenolic com-
pounds have anti-microbial or anti-bacterial properties. Thus,
these compounds are considered to be protective against low-
grade infections often associated with IR(127,130). Interestingly,
specific fractions of coconut oil, extracted under hot con-
ditions, have been shown to reduce blood glucose, cholesterol
and lipid peroxidation, and some polyphenolic compounds
appear to reduce liver lipid peroxidation(156,157).
Coconut oil and blood–brain barrier
The blood–brain barrier (BBB) is a brain endothelial structure
of the fully differentiated neurovascular system(158) that pro-
tects the brain from foreign substances. It is noted that more
than 98 % of all small-molecule drugs, and approximately
100 % of all large-molecule drugs or genes, do not cross the
BBB(159). Thus, it is very difficult to develop effective new
neurotherapeutics for AD that permeate the BBB. However,
there is literature that indicates that circulating D-b-3hydroxy-
butyrate ketone body, which is formed out of MCFA, crosses
the BBB and enters the mitochondria where it is metabolised
to AcAc and converted to acetyl-CoA, which enters into the
Krebs cycle(160). One in vivo study with mice has identified
the capacity of caprylic acid, a constituent of coconut oil, to
cross the BBB. This study indicates that as a result of crossing
the BBB, caprylic acid demonstrated anti-convulsant and a
neuroprotective effect(161).
Coconut water
In countries where coconuts are a primary produce, coconut
water is a common beverage. Coconut water contains a
range of beneficial ingredients, including vitamins, minerals,
antioxidants, amino acids, enzymes, growth factors and other
nutrients(162). Cytokinins, a class of plant growth hormones
(phytohormones) present in coconut water, influence plant
cell division, and are considered to have anti-ageing proper-
ties(163,164). There are two types of cytokinins: adenine-type
cytokinins (kinetin, zeatin and 6-benzylaminopurine) and
phenylurea-type cytokinins (diphenylurea and thidiazuron).
Recent studies have investigated the possibility of using
trans-zeatin as a treatment drug for neuronal diseases including
AD. Zeatin has demonstrated antioxidant and cell protective
effects against Ab-induced neurotoxicity in cultures of neuronal
PC12 cells, and in experiments of mice treated with scopola-
mine to induce amnesia, pretreatment of the mice with zeatin
caused a reduction in the level of induced amnesia, according
to the passive avoidance test and Y maze test(165). Interestingly,
another study has found that trans-zeatin could inhibit
acetylcholinesterase(166,167). This indicates that cytokinin
could have therapeutic value, as levels of the neurotransmitter
acetylcholine are reduced in AD, and acetylcholinesterase
inhibitors are currently used to ameliorate the symptoms of AD.
Coconut water has also been shown to have beneficial
effects on serum and tissue lipid parameters, when given to
rats concurrently fed a high-cholesterol containing diet(168).
Another study has investigated the positive effect of regular
consumption of two tropical food drinks, coconut (C. nuci-
fera) water and mauby (Colubrina arborescens), on the control
of hypertension(169). The combined products were found to be
almost twice as effective as the products in isolation.
Other coconut food products
Apart from coconut water and extracted coconut oil, the coco-
nut has a number of other culinary uses. The fleshy part of the
seed, the coconut meat, can be used fresh or dried in cooking.
Coconut cream and coconut milk are made by pressing the
flesh to extract fluid, and these are used in many countries
in cooking; for example, coconut milk is a component of
many curries in India, Sri Lanka and other Asian countries.
Desiccated coconut and coconut flour are also used in cook-
ing and baking. Other products include coconut chips and
flakes. Each of these products has a lipid (MCFA) component,
and may also contain high levels of both soluble and insoluble
fibre, as well as varying levels of the antioxidants and other
beneficial components already mentioned above. Research
has shown that many of these coconut products can improve
lipid profiles as well as provide other benefits. For example,
one study(170) has shown that the consumption of coconut
milk does not elevate serum lipid levels, and another
study(171) has found that a coconut milk porridge fed to
sixty healthy people 5 d a week for 8 weeks caused a decrease
in LDL levels and an increase in HDL levels. Further studies
should be carried out to help validate these significant benefits
of consuming coconut milk and cream, and to determine
whether such benefits are counteracted by any unfavourable
changes to serum lipid profiles. In another study(172), coconut
flakes have been shown to reduce total cholesterol as well as
LDL-C and serum TAG levels. Coconut residue after fluid
extraction has a high percentage of soluble (3·41 g/100 g)

















and insoluble (34·0 g/100 g) dietary fibre(173), and such high
fibre content has been suggested to contribute to many of
coconut’s health benefits as in the coconut flake study
mentioned above.
Salil et al.(174) demonstrated an improvement in diabetic
indicators following the consumption of coconut flesh; in
this case, it is believed to be due to the protein content of
coconut(175). The coconut kernel protein is rich in arginine,
and the observed anti-diabetic activity of coconut flesh has
been suggested to be due to the provision of arginine,
which has been shown to influence pancreatic b cell regener-
ation(174,175). Similarly, another study has found that coconut
water has a blood glucose-lowering effect and that coconut
milk has a regenerative effect on the pancreatic cells damaged
by diabetes(87). Arginine is a precursor of NO, produced by
the endothelial isoform of NO synthase, and NO is a signalling
molecule that has a direct influence on insulin sensitivity.
Maintaining NO production is also thought to be important
in reducing cardiovascular complications of diabetes: arginine
availability impacts on NO production, which can expand
the blood vessels, allowing for the BP in the patients to be
reduced(176).
Conclusions
The consumption and use of coconut in its various forms has a
long and established history in medicinal, scientific and nutri-
tional arenas. While consumed prolifically in regions engaged
in coconut primary production, Western cultures have tended
to highlight the fatty acid content, particularly the saturated fat,
and therefore limited its culinary usage.
The lipid content of coconut, being mostly MCFA, offers an
energy source that bypasses the usual glucose pathway, in the
form of ketone bodies, and without the associated fat depo-
sition often caused by LCFA. Despite the positive effect of a
KD, whether the KD influences b-amyloid levels and protects
against AD requires further study. The dosage of ketones and
the duration relevant to the AD also needs to be investigated.
At this time, it is not clear whether ketone bodies produced
from coconut oil has a direct effect on AD, specifically in
relation to slowing or clearance of Ab and t pathologies –
and if so, under what conditions. Furthermore, research
needs to be conducted to quantify the yield of ketones from
VCO, and support the ability of coconut derivatives to cross
the BBB, to establish likely efficacy.
However, evidence to suggest that coconut may lower total
and LDL-C, reduce systolic BP and ameliorate IR is of particu-
lar interest, in relation to AD risk reduction. A small number of
clinical trials and animal studies using a formulation of MCT
have reported significant improvement of cognition in AD
patients. At the same time, studies in which the diet has
been supplemented with SFA, particularly hydrogenated coco-
nut oil, have reported deleterious effects on hippocampal
morphology and behaviour, and increased plasma LDL levels.
Evidence suggests that despite coconut being a saturated
fat, it may not pose the usual negative effects on lipid profiles;
however, the influence on neuronal function and survival, as
well as cardiovascular effects remains unknown. While the
nutritional components of coconut are well accepted, incon-
sistencies in the data, it is suggested that further research
needs to be undertaken before broadly advocating the use
of coconut oil in addition to existing fat consumption or in
substitution.
Coconut is, however, widely available, inexpensive, non-
toxic and highly palatable, and consuming a regular intake
of good quality coconut oil or another coconut product may
become a simple yet important dietary change that may be
shown in the future to reduce the risk of AD. However,
research has suggested that the extraction method used to
obtain VCO appears to affect the quality of coconut oil and
may directly affect the efficacy. If specific extraction methods
are essential to achieve efficacy, only particular preparations
may confer benefit. Once this is known, further analysis
needs to be undertaken regarding the absorption process,
recommended dose, and whether it should be taken in
combination with other food groups or in isolation.
It must be emphasised that the use of coconut oil to treat
or prevent AD is not supported by any peer-reviewed
large cohort clinical data; any positive findings are based
on small clinical trials and on anecdotal evidence; however,
coconut remains a compound of interest requiring further
investigation.
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